Eye

Intrepid Automation Partners With Greater Than Tech, Collins Aerospace, and University of San Diego to Offer “Girl Meets Additive Manufacturing” Camp for High School Students

Retrieved on: 
Tuesday, August 9, 2022 - 1:56am

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220808005827/en/
    "Girl Meets Additive Manufacturing" Camp Information (Graphic: Business Wire)
    The Girl Meets Additive Manufacturing program, open to San Diego high school students, will introduce participants to additive manufacturing methods, 3D print technology, and engineering basics for industrial manufacturing.
  • Were looking forward to seeing what the students present, and hoping to spark interest in manufacturing as a career, says Maddi Stadtmueller, senior chemical applications engineer at Intrepid Automation.
  • Collins Aerospace looks forward to continuing to create pathways such as this one to introduce and develop our future workforce.
  • Collins Aerospace, a Raytheon Technologies Corp. business, is a leader in technologically advanced and intelligent solutions for the global aerospace and defense industry.

X Financial Reports Second Quarter 2022 Unaudited Financial Results

Retrieved on: 
Monday, August 8, 2022 - 10:00pm

SHENZHEN, China, Aug. 8, 2022 /PRNewswire/ -- X Financial (NYSE: XYF) (the "Company" or "we"), a leading online personal finance company in China, today announced its unaudited financial results for the second quarter ended June 30, 2022.

Key Points: 
  • SHENZHEN, China, Aug. 8, 2022 /PRNewswire/ -- X Financial (NYSE: XYF) (the "Company" or "we"), a leading online personal finance company in China, today announced its unaudited financial results for the second quarter ended June 30, 2022.
  • Income from operations in the second quarter of 2022 was RMB193.8 million (US$28.9 million), compared with RMB337.7 million in the same period of 2021.
  • Net income in the second quarter of 2022 was RMB185.7 million (US$27.7 million), compared with RMB223.4 million in the same period of 2021.
  • Net income for the second quarter of 2022 improved to RMB185.7 million from RMB139.9 million in the previous quarter, and Non-GAAP adjusted net income for the second quarter of 2022 was RMB210.7 million, representing an increase of 36.9% quarter-over-quarter.

Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million

Retrieved on: 
Monday, August 8, 2022 - 9:30pm

Under the terms of the agreement, Clearside will receive an initial payment of $32.5 million, less certain expenses.

Key Points: 
  • Under the terms of the agreement, Clearside will receive an initial payment of $32.5 million, less certain expenses.
  • The terms of the agreement also provide for an additional milestone payment of $20 million to Clearside upon attainment of a second pre-specified 2024 sales milestone for XIPERE.
  • The arrangement with HealthCare Royalty specifically excludes all Clearsides internal development programs, including CLS-AX, as well as any future in-licensed assets.
  • HEALTHCARE ROYALTY PARTNERS is a registered trademark of HealthCare Royalty Management, LLC in the U.S. and a trademark in other countries.

Annexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022 - 9:01pm

BRISBANE, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today outlined progress across its broad pipeline of fit-for-purpose product candidates and anticipated clinical milestones, and reported second quarter 2022 financial results.

Key Points: 
  • Annexon was founded with an ambitious goal: deliver game-changing treatments to patients suffering from complement-mediated diseases by stopping the classical complement cascade at its start.
  • With the proceeds from our recent financing, we are well-positioned to execute our milestones with a multi-year runway into the second half of 2025.
  • Overall, were invigorated by the promise of our platform and pipeline to make a meaningful difference in the treatment landscape for patients.
  • Annexon is rigorously developing a pipeline of diversified product candidates across multiple mid- to late- stage clinical trials, with clinical data anticipated throughout 2022 and 2023.

Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update

Retrieved on: 
Monday, August 8, 2022 - 9:01pm

Net product revenue of DEXTENZA for the quarter was $12.1 million, a 9% increase over the second quarter of 2021.

Key Points: 
  • Net product revenue of DEXTENZA for the quarter was $12.1 million, a 9% increase over the second quarter of 2021.
  • Net product revenue of DEXTENZA in the second quarter of 2022 was $12.1 million versus $11.1 million in the comparable quarter of 2021, reflecting a 9% increase.
  • Non-cash charges for stock-based compensation and depreciation and amortization were $4.8 million in the second quarter of 2022 versus $4.9 million for the comparable quarter of 2021.
  • Members of the Ocular Therapeutix management team will host a live conference call and webcast today at 4:30 pm Eastern Time to review the Company's financial results and provide a general business update.

Companies are Moving Away from Mandatory Director Retirement Policies and Pursuing Other Ways to Achieve Board Refreshment

Retrieved on: 
Monday, August 8, 2022 - 6:00pm

While mandatory turnover policies have been on the decline, the analysis reveals that substantially more companies are now conducting comprehensive board evaluationsa combination of board, committee, and individual director assessments.

Key Points: 
  • While mandatory turnover policies have been on the decline, the analysis reveals that substantially more companies are now conducting comprehensive board evaluationsa combination of board, committee, and individual director assessments.
  • The report includes insights and dataas recent as July 2022relating to board refreshment policies and director evaluations at S&P 500 and Russell 3000 companies.
  • "Boards can use several mechanisms to promote board refreshment, including policies that require board turnover and trigger a discussion of turnover.
  • "Another sign that age-based director retirement policies are losing ground is that companies that have such policies are increasingly building in some flexibility.

PANORAMA EYECARE SPINS OFF NEW LASIK DIVISION AND ANNOUNCES PARTNERSHIP WITH DENVER BRONCOS

Retrieved on: 
Monday, August 8, 2022 - 4:05pm

FORT COLLINS, Colo., Aug. 8, 2022 /PRNewswire/ -- Panorama Eyecare (PEC), a physician-led management services organization and the largest comprehensive eye care organization in the Rocky Mountain region, announces the formation of Panorama LASIK a group of vision correction centers under the Panorama Eyecare. Panorama LASIK will be the LASIK Partner of the Denver Broncos.

Key Points: 
  • Panorama LASIK will be the LASIK Partner of the Denver Broncos.
  • Panorama LASIK launches as a division of Panorama Eyecare and LASIK Partner of the Denver Broncos.
  • Panorama LASIK is a division of the largest comprehensive eye care organization in the Rocky Mountain region, Panorama Eyecare (PEC).
  • Panorama LASIK will debut as the LASIK Partner of the Denver Broncos ahead of the Broncos first preseason game against the Dallas Cowboys on August 13th.

MakerSights Named to Fortune 100 Best Small Workplaces of 2022

Retrieved on: 
Monday, August 8, 2022 - 3:35pm

MakerSights , the leading Voice of Consumer workspace purpose-built for apparel, footwear, and accessories brands, has earned a coveted spot on the Fortune 100 Best Small Workplaces of 2022 list.

Key Points: 
  • MakerSights , the leading Voice of Consumer workspace purpose-built for apparel, footwear, and accessories brands, has earned a coveted spot on the Fortune 100 Best Small Workplaces of 2022 list.
  • The leadership team at MakerSights is committed to supporting employees and upholding the company values, which include:
    Bias for action: Think and act courageously.
  • And these small workplaces have proven that the inspiring cultures theyve created go head-to-head with those of any large corporation.
  • MakerSights is the leading Voice of Consumer workspace purpose-built for consumer insights and apparel, footwear, and accessories testing.

CHCI TO HONOR MUSIC LEGEND CELIA CRUZ AND SECRETARY XAVIER BECERRA AT THE 45TH ANNUAL AWARDS GALA

Retrieved on: 
Monday, August 8, 2022 - 2:00pm

"We are proud to celebrate and recognize these two trailblazers at our 45th Annual Awards Gala this year."

Key Points: 
  • "We are proud to celebrate and recognize these two trailblazers at our 45th Annual Awards Gala this year."
  • "We are thrilled to honor both Celia Cruz and Secretary Xavier Becerra at this year's gala.
  • Throughout her career, Celia Cruz redefined salsa, recording more than 80 albums and songs, earning 23 Gold Records, and winning five Grammy Awards.
  • Now, as part of Cruz's amazing musical legacy, The Celia Cruz Foundation raises funds for Hispanic students whose dream is to study music.

Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call

Retrieved on: 
Monday, August 8, 2022 - 2:00pm

ARLINGTON, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022.

Key Points: 
  • ARLINGTON, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022.
  • Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m.
  • The dial-in number to access the conference call is 800-715-9871 using the conference ID 9372651.
  • Kala is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye.